Application of phosphatidylserine (PS) blocking agent to preparation of medicines for treating platelet number reduction related diseases

A technology for phosphatidylserine and thrombocytopenia, applied in the field of platelet-related drugs, can solve problems such as shortening the lifespan of platelets, and achieve the effect of great scientific research and economic value

Active Publication Date: 2018-06-15
SUZHOU UNIV
View PDF9 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Technical problem to be solved: The pathogenesis of thrombocytopenia caused by different etiologies is due to the shortened lifespan of platelets caused by apoptosis and activation, and is cleared

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of phosphatidylserine (PS) blocking agent to preparation of medicines for treating platelet number reduction related diseases
  • Application of phosphatidylserine (PS) blocking agent to preparation of medicines for treating platelet number reduction related diseases
  • Application of phosphatidylserine (PS) blocking agent to preparation of medicines for treating platelet number reduction related diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0032] 1. Reagents and materials:

[0033] JC-1 was purchased from Biyuntian Company in China; FITC-human CD62P, PE-human CD41 and PE-mouse CD41 were purchased from American Biolegend Company; R300, FITC-mouse CD62P and PE-JON / A were purchased from German Emfret Company; FITC- PAC1 was purchased from BD Biosciences, USA; anti-Human-caspase-3 antibody was purchased from Biolegend, USA; Fermentas Protein Marker (10-170KD) was purchased from Thermo; FITC-lactadherin was purchased from Haematologic Technologies, USA; Normal Mouse IgG and Normal rat IgG were purchased from from Santa Cruz, USA; AN51 and SZ2 were provided by the Blood Research Institute of the First Affiliated Hospital of Soochow University.

[0034] 2. Experimental mice:

[0035] Wild type (WT) C57BL / 6 mice were purchased from Shanghai Slack Experimental Animal Co., Ltd. All experimental animal-related welfare is strictly implemented in accordance with the "Regulations on the Administration of Experimental Animal...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of phosphatidylserine (PS) blocking agent to preparation of medicines for treating platelet number reduction related diseases. The invention proves that PS exposurecaused by apoptotic and activated platelets promotes that the platelets are eliminated in liver through experiments for the first time. Research proves that the platelets in the body of a patient suffering from thrombocytopenia are subjected to both activation and apoptosis, and apoptosis and activation cause the PS of the platelets to be exposed, so that the platelets are swallowed by phagocyticcells in the liver. Closing of the PS or blockage of PS extroversion can inhibit the platelets from being eliminated, which indicates that the PS blocking agent can take part in the treatment processof the platelet number change related diseases and can inhibit platelet number reduction in peripheral circulation blood. Therefore, the invention discloses a mechanism for eliminating the plateletsthrough the PS extroversion; furthermore, the blocking agent for inhibiting from eliminating PS exposure dependency platelets has the potential to be developed into novel platelets protective medicines and medicines for treating thrombocytopenia, and has great scientific research and economic value.

Description

technical field [0001] The invention belongs to the field of platelet-related medicines, and in particular relates to the use of a phosphatidylserine (Phosphatidylserine, PS) blocker in the preparation of medicines for treating diseases related to platelet count reduction. Background technique [0002] Phosphatidylserine (PS) eversion is a common phenomenon in the later stages of platelet activation and apoptosis. Current studies have found that platelet apoptosis exists in physiological conditions, blood bank storage of platelets and many common diseases; while platelet activation exists in many common diseases such as infection, cancer and heart disease. In these common disorders in which platelet activation or apoptosis occurs, thrombocytopenia leading to fatal bleeding can occur. However, the pathological mechanism of how apoptotic or activated platelets are cleared from circulation and lead to thrombocytopenia remains unclear. [0003] Thrombocytopenia is a common cli...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61P7/04
CPCA61K45/00
Inventor 戴克胜
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap